Pre-made Natalizumab benchmark antibody ( Whole mAb, anti-ITGA4 therapeutic antibody, Anti-CD49D/IA4 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-367

Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-367-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody
INN Name Natalizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI Structure4irz:HL
95-98% SI StructureNone
Year Proposed1998
Year Recommended1999
CompaniesBiogen;Biogen Idec;Elan Corporation;Perrigo
Conditions ApprovedCrohn's disease;Multiple sclerosis
Conditions ActiveEpilepsy;Graft-versus-host disease;Stroke
Conditions DiscontinuedMultiple myeloma;Rheumatoid arthritis
Development Techna